ESR2 and cancer: Despite an increasing appreciation for its anticancer therapeutic potential, there lacks compelling genetic evidence for a definitive role of ERβ signaling in cancer development and progression, which dampers rationalized efforts to mobilize it with targeted precision and synergy.